Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.62 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | TEC | P42680 | 3/20 | 0.51 |
| ▸ | TXK | P42681 | 2/20 | 0.51 |
| ▸ | BMX | P51813 | 2/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | FGR | P09769 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | FRK | P42685 | 1/20 | 0.51 |
| ▸ | BLK | P51451 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | ITK | Q08881 | 1/20 | 0.51 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.51 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.51 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22940351 | 0.98 | BTK (0.61) | BTKEGFRTECTXKBMX | |
| SCHEMBL22940202 | 0.98 | BTK (0.61) | BTKEGFRTECTXKBMX | |
| SCHEMBL22940348 | 0.94 | BTK (0.60) | BTKEGFRTECTXKBMX | |
| SCHEMBL22940346 | 0.94 | BTK (0.60) | BTKEGFRTECTXKBMX | |
| SCHEMBL22940349 | 0.89 | BTK (0.62) | BTKEGFRTECTXKBMX | |
| SCHEMBL28711117 | 0.87 | BTK (0.50) | BTKEGFRTECTXKBMX | |
| SCHEMBL22941150 | 0.87 | BTK (0.61) | BTKEGFRTECTXKBMX | |
| SCHEMBL29414357 | 0.87 | BTK (0.50) | BTKEGFRTECTXKBMX | |
| SCHEMBL22941214 | 0.83 | BTK (0.60) | BTKEGFRTECTXKBMX | |
| SCHEMBL22940236 | 0.83 | BTK (0.60) | BTKEGFRTECTXKBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281876-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2022-09-08 | — | — | US | disclosed |
| WO-2021018018-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281876-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | BTK 1/4885EGFR 863/4885TEC 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.